Assembly Biosciences Near Breakout; Key Clinical Trials in Focus
AI Prediction of Assembly Biosciences, Inc. (ASMB)
Assembly Biosciences, a clinical-stage biotech company focusing on hepatitis B cures, has shown promising developments in its drug pipeline and strategic collaborations. Given the upcoming clinical trial results and potential regulatory milestones, investors may find significant opportunities for growth.
ASMB Report Information
Prediction Date2025-07-03
Close @ Prediction$18.14
Mkt Cap700m
IPO DateN/a
AI-derived Information
Recent News for ASMB
- Aug 20, 3:57 pm — Assembly Health Appoints Bracha Eidelman as General Manager, Quality (PRNewswire RSS)
- Aug 14, 4:05 pm — ASMB SEC filing points to financing activity (ScanScor Filing Bot)
- Aug 13, 4:15 pm — ASMB SEC filing points to financing activity (ScanScor Filing Bot)
- Aug 13, 4:13 pm — Assembly Biosciences: Q2 Earnings Snapshot (Associated Press)
- Aug 13, 4:11 pm — ASMB SEC filing points to financing activity (ScanScor Filing Bot)
- Aug 13, 4:00 pm — Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates (GlobeNewswire RSS)
- Aug 13, 12:47 pm — ASMB SEC filing points to financing activity (ScanScor Filing Bot)
- Aug 6, 2:01 pm — Assembly Health Appoints David Millen as Chief Technology Officer (PRNewswire RSS)
- May 28, 4:05 pm — Assembly Biosciences Announces Upcoming Investor Conference Presentations (GlobeNewswire RSS)
- May 27, 9:00 am — FormAssembly Achieves DoD IL4 Status in Partnership With FedHIVE (GlobeNewswire RSS)
- May 26, 4:05 pm — Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares (GlobeNewswire RSS)
- May 22, 7:05 am — Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire RSS)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.